Cyclosporin A: Review of results in organ and bone‐marrow transplantation in man
1984; Wiley; Volume: 4; Issue: 2 Linguagem: Inglês
10.1002/med.2610040205
ISSN1098-1128
Autores Tópico(s)Mesenchymal stem cell research
ResumoMedicinal Research ReviewsVolume 4, Issue 2 p. 221-265 Article Cyclosporin A: Review of results in organ and bone-marrow transplantation in man Claude Weil, Claude Weil Clinical Research, Sandoz Ltd., 4002 Basle, SwitzerlandSearch for more papers by this author Claude Weil, Claude Weil Clinical Research, Sandoz Ltd., 4002 Basle, SwitzerlandSearch for more papers by this author First published: April/June 1984 https://doi.org/10.1002/med.2610040205Citations: 22AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 P. Alexander, Cyclosporin A and the growth, dissemination and induction of tumours. in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 299. Web of Science®Google Scholar 2 M. C. Allwood and R. Lawrance, “High pressure liquid chromatographic determination of cyclosporin A in plasma,” J. Clin. Hosp. Pharmacy, 6, 195 (1981). 10.1111/j.1365-2710.1981.tb00992.x CASPubMedWeb of Science®Google Scholar 3 K. Atkinson, R. Short, and J. C. Biggs, “The use of cyclosporin-A as prophylaxis for graft versus host disease after allogeneic bone marrow transplantation in man,” Clin. Exp. Pharmacol. Physiol. 9, 540 (1982). Web of Science®Google Scholar 4 A. J. Barrett, J. R. Kendra, C. F. Lucas, D. V. Joss, R. Joshi, P. Pendharkar, and K. Hugh-Jones, “Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients,” Br. Med. J., 285, 162 (1982). 10.1136/bmj.285.6336.162 PubMedWeb of Science®Google Scholar 5 D. W. Van Bekkum, S. Knaan, and C. Zurcher, “Effects of cyclosporin A on experimental graft-versus-host disease in rodents,” Transplant Proc., 12, (2), 278 (1980). CASPubMedWeb of Science®Google Scholar 6 P. R. F. Bell, R. F. M. Wood, M. Peters, and J. R. Nash, “Comparison of various methods of chemical immunosuppression in islet cell transplantation,” Transplant Proc., 12 (No 2) 291 (1980). CASPubMedWeb of Science®Google Scholar 7 T. A. G. Bell, D. L. Easty, and K. G. McCullagh, “A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits,” Br. J. Ophthal., 66, 303 (1982). 10.1136/bjo.66.5.303 CASPubMedWeb of Science®Google Scholar 8 T. Beveridge, Pharmacokinetics and metabolism of Cyclosporin A, in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 35. Google Scholar 9 T. Beveridge, “Combined European experience with cyclosporin A in bone marrow transplantation,” Exp. Hematol., 10, (Suppl. 10), 88 (1982). Google Scholar 10 J. C. Biggs, K. Atkinson, J. Hayes, M. Ralston, A. J. Concannon, and A. J. Dodds, “After allogeneic bone marrow transplantation cyclosporin-A is associated with faster engraftment, less mucositis, and three distinct syndromes of nephrotoxicity when compared to methotrexate,” Exp. Hematol. 10, (Suppl. 11), 53 (1982) (Abstract No. 88). Google Scholar 11 A. G. Bird, Cyclosporin A, lymphomata and Epstein-Barr virus, in Cyclosporin A, D. J G. White, Ed. Elsevier, Amsterdam, 1982, p. 307. Google Scholar 12 K. S. Black, C. W. Hewitt, L. A. Fraser, J. G. Osborne, B. M. Achauer, D. C. Martin, and D. W. Furnas, “Cosmas and Damian in the laboratory,” New Eng. J. Med., 306, 368 (1982). 10.1056/NEJM198202113060620 PubMedWeb of Science®Google Scholar 13 J. F. Borel and J. Meszaros, “Skin transplantation in mice and dogs,” Transplantation, 29, 161 (1980). CASPubMedWeb of Science®Google Scholar 14 J. C. C. Borleffs, Z. de By-Aghai, and R. L. Marquet, “Beneficial influence of cy-closporin A and standard immunosuppression on kidney graft survival in transfused rhesus monkeys,” Transplantation 32, 161 (1981). 10.1097/00007890-198108000-00017 PubMedWeb of Science®Google Scholar 15 J. C. C. Borleffs, P. Neuhaus, R. L. Marquet, C. Zurcher, and H. Balner, Cyclosporin A and kidney transplantation in rhesus monkeys, in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 329. Google Scholar 16 R. Y. Calne, “Immunosuppression for organ grafting—observations on Cyclosporin A,” Immunol. Rev., 46, 113 (1979). 10.1111/j.1600-065X.1979.tb00286.x CASPubMedWeb of Science®Google Scholar 17 R. Y. Calne, K. Rolles, D. J. G. White, S. Thiru, D. B. Evans, R. Henderson, D. L. Hamilton, N. Boone, P. McMaster, O. Gibby, and R. Williams, “Cyclosporin-A in clinical organ grafting,” Transplant. Proc., 13, (No. 1), 349 (1981). CASPubMedWeb of Science®Google Scholar 18 R. Y. Calne, K. Rolles, D. J. G. White, S. Thiru, D. B. Evans, P. McMaster, D. C. Dunn, G. N. Craddock, R. G. Henderson, S. Aziz, and P. Lewis, “Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers,” Lancet, 2, 1033 (1979). 10.1016/S0140-6736(79)92440-1 CASPubMedWeb of Science®Google Scholar 19 R. Y. Calne and D. J. G. White, “Cyclosporin-A—a powerful immunosuppressant in dogs with renal allografts,” IRCS Med. Sci. 5, 595 (1977). CASGoogle Scholar 20 R. Y. Calne and D. J. G. White, “The use of Cyclosporin A in clinical organ grafting,” Ann. Surg. 196, 330 (1982). 10.1097/00000658-198209000-00012 CASPubMedWeb of Science®Google Scholar 21 R. Y. Calne, D. J. G. White, D. B. Evans, S. Thiru, R. G. Henderson, D. V. Hamilton, K. Rolles, P. McMaster, T. J. Duffy, B. R. D. MacDougall, and R. Williams, “Cyclosporin A in cadaveric organ transplantation,” Br. Med. J., 282, 934 (1981). 10.1136/bmj.282.6268.934 CASPubMedWeb of Science®Google Scholar 22 R. Y. Calne, D. J. G. White, D. B. Evans, and C. Wight, “ Three years' experience with cyclosporin A in clinical cadaveric kidney transplantation,” in Cyclosporin A, D. J. G. White, Ed., Elsevier, Amsterdam, 1982, p. 347. Google Scholar 23 R. Y. Calne, D. J. G. White, B. D. Pentlow, K. Rolles, T. Syrakos, T. Ohtawa, D. P. Smith, P. McMaster, D. B. Evans, B. M. Herbertson, and S. Thiru, “Cyclosporin A: Preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants,” Transplant Proc. 11(No 1), 860 (1979). CASPubMedWeb of Science®Google Scholar 24 R. Y. Calne, D. J. G. White, K. Rolles, T. J. Duffy, and T. Kass, “Renal and segmental pancreatic grafting with draining of exocrine secretion and continuous intravenous cyclosporin A in a patient with insulin-dependent diabetes and renal failure,” Br. Med. J., 285, 677 (1982). 10.1136/bmj.285.6343.677 CASPubMedWeb of Science®Google Scholar 25 R. Y. Calne, D. J. G. White, K. Rolles, D. P. Smith, and B. M. Herbertson, “Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A,” Lancet 1, 1183 (1978). 10.1016/S0140-6736(78)90971-6 CASPubMedWeb of Science®Google Scholar 26 R. Y. Calne, D. J. G. White, S. Thiru, D. B. Evans, P. McMaster, D. C. Dunn, G. N. Craddock, B. D. Pentlow, and K. Rolles, “Cyclosporin A in patients receiving renal allografts from cadaver donors,” Lancet, 2, 1323 (1978). 10.1016/S0140-6736(78)91970-0 CASPubMedWeb of Science®Google Scholar 27 Canadian Multicentre Transplant Study Group, “A randomized clinical trial of Cy-closporine in cadaveric renal transplantation,” New Eng. J. Med., 309, 809 (1983). 10.1056/NEJM198310063091401 PubMedWeb of Science®Google Scholar 28 B. J. Carpenter, N. L. Tilney, T. B. Strom, M. R. Garovoy, and J. M. Lazarus, “Cyclosporin A in cadaver renal allografts,” Kidney Int., 19, 265 (1981). Web of Science®Google Scholar 29 R. A. Clift, C. D. Buckner, E. D. Thomas, K. Doney, A. Fefer, P. E. Neiman, J. Singer, J. Sanders, P. Stewart, K. M. Sullivan, J. Deeg, and R. Storb, “Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation,” Lancet, 2, 621 (1982). 10.1016/S0140-6736(82)92735-0 CASPubMedWeb of Science®Google Scholar 30 A. B. Cosimi, C. F. Shield, C. Peters, R. C. Burton, G. Scott, and P. S. Russel, “Prolongation of allograft survival by cyclosporin A.” Surg. Forum, 30, 287 (1979). CASPubMedWeb of Science®Google Scholar 31 C. Cunningham, M. D. Burke, P. H. Whiting, J. G. Simpson, and D. N. Wheatley, “Ketoconazole, cyclosporin, and the kidney,” Lancet, 2, 1464 (1982). 10.1016/S0140-6736(82)91366-6 CASPubMedWeb of Science®Google Scholar 32 T. K. Daneshmend, “Ketaconazole-cyclosporin interaction,” Lancet, 2, 1342 (1982). 10.1016/S0140-6736(82)91545-8 CASPubMedWeb of Science®Google Scholar 33 H. J. Deeg, “Allogeneic marrow transplantation for acute nonlymphoblastic leukemia (ANL) in first remission: A randomized trial comparing the effect of methotrexate (MTX) and cyclosporin A (CYA) on graft-versus-host disease (GVHD) and survival,” Exp. Hematol., 10, Suppl. 11, 48 (1982) (abstract No 80). Google Scholar 34 H. J. Deeg, R. Storb, L. Gerhard-Miller, H. M. Shulman, P. L. Weiden, and E. D. Thomas, “Cyclosporin A, a powerful immunosuppressant in vivo and in vitro in the dog, fails to induce tolerance,” Transplantation, 29, 320 (1980). 10.1097/00007890-198003000-00014 PubMedWeb of Science®Google Scholar 35 H. J. Deeg, R. Storb, P. L. Weiden, T. Graham, K. Atkinson, and E. D. Thomas, “Cydosporin-A: effect on marrow engraftment and graft-versus-host disease in dogs,” Transplant Proc., 13(No 1), 402 (1981). CASPubMedWeb of Science®Google Scholar 36 S. Denham, J. M. Styles, R. K. Barfoot, and C. J. Dean, “Reversible suppression of allo-antibody production by cyclosporin A,” Int. Arch. Allergy, Appl. Immunol., 62, 453 (1980). 10.1159/000232548 CASPubMedWeb of Science®Google Scholar 37 H. Dieperink and J. Møller, “Ketoconazole and cyclosporin,” Lancet, 2, 1217 (1982). 10.1016/S0140-6736(82)91231-4 CASPubMedWeb of Science®Google Scholar 38 P. Donatsch, E. Abisch, M. Homberger, R. Traber, M. Trapp, and R. Voges, “A radioimmunoassay to measure Cyclosporin A in plasma and serum samples,” J. Immunoassay, 2(No. 1), 19 (1981). 10.1080/01971528108062989 CASPubMedGoogle Scholar 39 J. M. Dubernard, J. Traeger, A. Gelet, A. Secchi, J. L. Touraine, X. Martin, M. C. Malik, and M. Devonec, “Clinical experience with 27 pancreatic allografts in man,” in 9th International Congress of The Transplantation Society, Brighton, UK, 1982 (abstract No F2.6). Google Scholar 40 D. C. Dunn, “The specificity of post-cyclosporin ‘tolerance’, Transplant Proc., 13 (No. 1), 383 (1981). CASPubMedWeb of Science®Google Scholar 41 D. C. Dunn, D. J. G. White, and B. M. Herbertson, “Persistent nonspecific immu-nosuppression after a course of cyclosporin A,” Transplantation, 29, 349 (1980). 10.1097/00007890-198004000-00021 CASPubMedWeb of Science®Google Scholar 42 D. C. Dunn, D. J. G. White, and J. Wade, “Survival of first and second kidney allografts after withdrawal of Cyclosporin A' therapy,” IRCS Med. Sci. 6, 464 (1978). Google Scholar 43 D. F. DuToit, H. Reece-Smith, P. McShane, T. Denton, and P. J. Morris, “Effect of cyclosporin A on allotransplanted pancreatic fragments to the spleen of totally pan-createctomized dogs,” Transplantation, 33, 302 (1982). 10.1097/00007890-198203000-00018 CASPubMedWeb of Science®Google Scholar 44 D. F. DuToit, H. Reece-Smith, P. McShane, T. Denton, and P. J. Morris, “Prolongation of segmental pancreatic allografts in dogs receiving cyclosporin A,” Transplantation, 33, 432 (1982). 10.1097/00007890-198204000-00019 CASPubMedWeb of Science®Google Scholar 45 European Multicentre Trial, “Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors.” Lancet, 2, 57 (1982). PubMedWeb of Science®Google Scholar 46 European Multicentre Trial, “Steroidfreie Behandlung nierentransplantierter Patien-ten mit Cyclosporin A.” Klin. Wschr., 60, 1137 (1982). 10.1007/BF01715843 Web of Science®Google Scholar 47 R. M. Ferguson, J. J. Rynasiewicz, D. E. R. Sutherland, R. L. Simmons, and J. S. Najarian, “Cyclosporin A in renal transplantation: a prospective randomized trial,” Surgery, 92, 175 (1982). CASPubMedWeb of Science®Google Scholar 48 R. M. Ferguson, D. E. R. Sutherland, R. L. Simmons, and J. S. Najarian, “Ketoconazole, cyclosporin metabolism, and renal transplantation,” Lancet, 2, 882 (1982). 10.1016/S0140-6736(82)90851-0 CASPubMedWeb of Science®Google Scholar 49 O. N. Fernando, P. Sweny, K. Farrington, H. Rogers, R. A. Baillod, M. K. Chan, Z. Varghese, and J. F. Moorhead, “Preliminary experience with cyclosporin A in human renal allografts,” Transplant Proc., 12, (No. 2), 244 (1980). CASPubMedWeb of Science®Google Scholar 50 S. Flechner, R. H. Kerman, C. T. Van Buren, W. D. Payne, and B. D. Kahan, “The use of cyclosporin A for high MLC haplo-identical living related renal transplants,” in 9th International Congress of The Transplantation Society, Brighton, UK, 1982 (abstract No F4.2). Google Scholar 51 R. P. Gale, H. E. M. Kay, A. A. Rimm, and M. M. Bortin, “Bone-marrow transplantation for acute leukaemia in first remission,” Lancet, 2, 1006 (1982). 10.1016/S0140-6736(82)90048-4 PubMedWeb of Science®Google Scholar 52 J. F. W. Garvey, P. McShane, M. D. Poole, P. R. Millard, and P. J. Morris, “The effect of cyclosporin A on experimental pancreas allografts in the rat,” Transplant Proc. 12, (No. 2), 266 (1980). CASPubMedWeb of Science®Google Scholar 53 E. Gluckman, “Report of the EGBMT working party on severe aplastic anemia,” Exp. Hematol., 10, Suppl. 10, 14 (1982). Google Scholar 54 E. Gluckman, W. Arcese, A. Devergie, and M. Boiron, “Cyclosporin-A prophylactic treatment of graft-versus-host disease in human allogeneic bone marrow transplantation: preliminary results,” Transplant Proc. 13(No 1), 368 (1981). CASPubMedWeb of Science®Google Scholar 55 E. Gluckman, A. Devergie, and J. Dutreix, “Bone marrow transplantation in Fanconi anemia. A modified conditioning regimen,” Exp. Hematol., 10, Suppl. 10, 26 (1982). PubMedGoogle Scholar 56 E. Gluckman, A. Devergie, F. Lokiec, O. Poirier, and A. Baumelou, “Nephrotoxitity of cyclosporin A in bone-marrow transplantation,” Lancet, 2, 144 (1981). 10.1016/S0140-6736(81)90320-2 CASPubMedWeb of Science®Google Scholar 57 F. C. Goetz, D. E. R. Sutherland, B. A. Elick, J. S. Najarian, “Pancreas transplantation for diabetes: clinical experience and metabolic studies,” in 9th International Congress of The Transplantation Society, Brighton, UK, 1982 (abstract No S8.6). Google Scholar 58 J. M. Goldman, A. S. J. Baughan, D. M. McCarthy, A. M. Worsley, J. M. Hows, E. C. Gordon-Smith, D. Catovsky, J. R. Batchelor, A. W. G. Goolden, and D. A. G. Galton, “Marrow transplantation for patients in the chronic phase of chronic gran-ulocytic leukaemia,” Lancet, 2, 623 (1982). 10.1016/S0140-6736(82)92736-2 PubMedWeb of Science®Google Scholar 59 J. M. Goldman, L. Learney, A. Worsley, A. Baughan, D. Catovsky, E. C. Gordon-Smith, A. W. G. Goolden, and D. A. G. Galton, “Bone marrow transplantation for patients with chronic granulocytic leukaemia,” Exp. Hematol. 10, Suppl. 11, 18 (1982) (abstract No. 28). CASPubMedGoogle Scholar 60 A. Gratwohl, I. Forster, and B. Speck, “Skin grafts in rabbits with cyclosporin A,” Transplantation, 31, 136 (1981). 10.1097/00007890-198102000-00011 CASPubMedWeb of Science®Google Scholar 61 A. Gratwohl, I. Forster, and B. Speck, “Histoincompatible skin and marrow grafts in rabbits on cyclosporin A,” Transplantation, 33, 361 (1982). 10.1097/00007890-198204000-00004 CASPubMedWeb of Science®Google Scholar 62 A. Gratwohl, M. Müller, B. Osterwalder, C. Nissen, and B. Speck, “Nephrotoxicity of cyclosporin A in bone marrow transplant recipients,” Lancet, 2, 635 (1981). 10.1016/S0140-6736(81)92769-0 CASPubMedWeb of Science®Google Scholar 63 A. Gratwohl, B. Osterwalder, D. Ruggero, C. Nissen, P. Cornu, and B. Speck, “Prophylaxis of graft-versus-host disease with Cyclosporin-A,” Blut, 14, 180 (1980). Google Scholar 64 C. J. Green and A. C. Allison, “Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment,” Lancet, 1, 1182 (1978). 10.1016/S0140-6736(78)90970-4 CASPubMedWeb of Science®Google Scholar 65 C. J. Green, A. C. Allison, and S. Precious, “Induction of specific tolerance in rabbits by kidney allografts and short periods of cyclosporin-A treatment,” Lancet, 2, 123 (1979). 10.1016/S0140-6736(79)90005-9 CASPubMedWeb of Science®Google Scholar 66 C. J. Green, G. Grimaldi, S. Simpkin, and A. Johnson, “Immunosuppression of rabbit ovarian and adnexal allografts with cyclosporin A,” IRCS Med. Sci. 10, 176 (1982). CASWeb of Science®Google Scholar 67 C. J. Green, E. Kemp, G. Kemp, S. Larsen, H. Starklint, and S. Simpkin, Prolongation of concordant renal xenografts in rabbit recipients by a short course of Cyclosporin A treatment. in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 155. Google Scholar 68 B. P. Griffith, R. L. Hardesty, G. M. Deeb, T. E. Starzl, and H. T. Bahnson, “Cardiac transplantation with cyclosporin A and prednisone,” Ann. Surg. 196 (No. 3 Suppl., ), 324 (1982). 10.1097/00000658-198209000-00011 CASPubMedWeb of Science®Google Scholar 69 A. K. Gulati and A. A. Zalewski, “Muscle allograft survival after cyclosporin A immunosuppression,” Exp. Neural., 77, 378 (1982). 10.1016/0014-4886(82)90251-5 CASPubMedWeb of Science®Google Scholar 70 T. R. Hakala, T. E. Starzl, J. T. Rosenthal, B. W. Shaw, Jr., and S. Iwatsuki, “Cadaveric renal transplantation with cyclosporin A and steroids,” in 9th International Congress of The Transplantation Society, Brighton, UK, 1982 (abstract No F4.6). Google Scholar 71 D. V. Hamilton, D. B. Evans, and S. Thiru, Toxicity of Cyclosporin A in organ grafting, in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 393. Google Scholar 72 P. Häyry, J. Ahonen, E. von Willebrand, B. Eklund, K. Höckekstedt, A. Kauste, E. Taskinen, I. Lautenschlager, M. Lalla, and H. Sarelin, “Effect of cyclosporin A on the in situ inflammatory response of human renal allograft rejection,” Scand. J. Immunol., 16, 135 (1982). 10.1111/j.1365-3083.1982.tb00707.x CASPubMedWeb of Science®Google Scholar 73 W. P. Homan, J. W. Fabre, M. E. French, P. R. Millard, T. G. Denton, and P. J. Morris, “Reversal of acute rejection episodes by cyclosporin A in dogs receiving renal allografts,” Transplantation, 29, 262 (1980). 10.1097/00007890-198003000-00021 CASPubMedWeb of Science®Google Scholar 74 W. P. Homan, J. W. Fabre, K. A. Williams, P. R. Millard, and P. J. Morris, “Studies on the immunosuppressive properties of cyclosporin A in rats receiving renal allografts,” Transplantation, 29, 361 (1980). 10.1097/00007890-198005000-00003 CASPubMedWeb of Science®Google Scholar 75 W. P. Homan, M. E. French, J. W. Fabre, P. R. Millard, T. G. Denton, and P. J. Morris, “The interaction of cyclosporin A with other immunosuppressive agents in dog recipients of renal allografts,” Transplant Proc. 12, (No 2), 287 (1980). CASPubMedWeb of Science®Google Scholar 76 W. P. Homan, M. E. French, P. R. Millard, and P. J. Morris, “A study of eleven drug regimens using cyclosporin-A to suppress renal allograft rejection in the dog,” Transplant Proc. 13(No 1), 397 (1981). CASPubMedWeb of Science®Google Scholar 77 W. P. Homan, K. A. Williams, J. W. Fabre, P. R. Millard, and P. J. Morris, “Prolongation of cardiac xenograft survival in rats receiving cyclosporin A,” Transplantation, 31, 164 (1981). 10.1097/00007890-198103000-00004 CASPubMedWeb of Science®Google Scholar 78 W. P. Homan, K. A. Williams, P. R. Millard, and P. J. Morris, “Prolongation of renal allograft survival in the rat by pretreatment with donor antigen and cyclosporin A,” Transplantation, 31, 423 (1981). 10.1097/00007890-198106000-00004 CASPubMedWeb of Science®Google Scholar 79 R. Hoover and J. F. Fraumeni, Jr., “Risk of cancer in renal-transplant recipients,” Lancet, 2, 55 (1973). 10.1016/S0140-6736(73)93256-X CASPubMedWeb of Science®Google Scholar 80 J. Hows, R. Harris, S. Palmer, and E. C. Gordon-Smith, “Immunosuppression with Cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anaemia: preliminary studies,” Br. J. Haematol., 48, 227 (1981). 10.1111/j.1365-2141.1981.tb02708.x CASPubMedWeb of Science®Google Scholar 81 J. M. Hows, S. Palmer, and E. C. Gordon-Smith, “Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia,” Transplantation, 33, 382 (1982). 10.1097/00007890-198204000-00008 CASPubMedWeb of Science®Google Scholar 82 J. M. Hows, S. Palmer, and E. C. Gordon-Smith, Cyclosporin A in compatible grafting for severe aplastic anaemia, in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 511. Google Scholar 83 J. M. Hows, S. Palmer, S. Want, C. Dearden, and E. C. Gordon-Smith, “Serum levels of cyclosporin A and nephrotoxicity in bone marrow transplant patients,” Lancet, 2, 145 (1981). 10.1016/S0140-6736(81)90321-4 CASPubMedWeb of Science®Google Scholar 84 W. Huber, M. Spielberger, P. Riegler, F. Neumair, R. Benelli, B. Giacon, D. Di Landro, and R. Margreiter, “The use of cyclosporin A in patients receiving renal allografts from cadaver donors,” Kidney Int., 22, 97 (1982). Web of Science®Google Scholar 85 P. A. Hunter, K. R. Wilhelmus, N. S. C. Rice, and B. R. Jones, “Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection,” Clin. Exp. Immunol., 45, 173 (1981). CASPubMedWeb of Science®Google Scholar 86 I. F. Hutchinson, C. A. Shadur, A. Durate, W. M. Baldwin, III, T. B. Strom, and N. L. Tilney, “Effects of cyclosporin A on host responses to cardiac allografts in rats,” Surg. Forum, 31, 373 (1980). CASWeb of Science®Google Scholar 87 S. Iwatsuki, B. W. Shaw, Jr., and T. E. Starzl, “Biliary tract complications in 51 consecutive liver recipients under cyclosporin A-steroid therapy,” in 9th International Congress of The Transplantation Society, Brighton, UK, 1982 (Abstract No. F10.4). Google Scholar 88 P. Jacobs, Effect of cyclosporin A on the incidence of graft-versus-host disease (GVHD) and survival of rabbits following allogeneic bone marrow transplantation, in Experimental Hematology Today 1981, S. J. Baum, G. D. Ledney, and A. Khan, Eds., Karger, Basel, 1981, p. 87. Google Scholar 89 P. Jacobs and E. C. Gordon-Smith, Cyclosporin A, transplantation, and lymphoma, Lancet, 2, 1296 (1980). 10.1016/S0140-6736(80)92354-5 CASPubMedWeb of Science®Google Scholar 90 S. W. Jamieson, N. A. Burton, C. P. Bieber, B. A. Reitz, P. E. Oyer, E. B. Stinson, and N. E. Shumway, “Cardiac-allograft survival in primates treated with cyclosporin A,” Lancet, 1, 545 (1979). 10.1016/S0140-6736(79)90959-0 CASPubMedWeb of Science®Google Scholar 91 S. W. Jamieson, N. A. Burton, C. P. Bieber, B. A. Reitz, P. E. Oyer, E. B. Stinson, and N. E. Shumway, “Survival of cardiac allografts in rats treated with cyclosporin A,” Surg. Forum, 30, 289 (1979). CASPubMedWeb of Science®Google Scholar 92 B. D. Kahan, C. T. Van Buren, S. N. Lin, Y. Ono, G. Agostino, S. J. LeGrue, M. Boileau, W. D. Payne, and R. H. Kerman, “Immunopharmacological monitoring of cyclosporin A-treated recipients of cadaveric kidney allograts,” Transplantation, 34, 36 (1982). 10.1097/00007890-198207000-00007 CASPubMedWeb of Science®Google Scholar 93 B. D. Kahan, C. T. Van Buren, S. N. Lin, M. Ried, and S. J. LeGrue, Pharmaco-kinetics of Cyclosporin A in renal allograft recipients, in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 413. Google Scholar 94 K. Kawahara, D. E. R. Sutherland, J. J. Rynasiewicz, and J. S. Najarian, “Prolongation of heterotopic cardiac allografts in rats by cyclosporin A,” Surgery, 88, 594 (1980). CASPubMedWeb of Science®Google Scholar 95 M. S. Kennedy, H. J. Deeg, R. Storb, and E. D. Thomas, “Cyclosporin A (CYA) in marrow transplantation: toxicity and concentration dependent immunosuppression in vivo,” in 9th International Congress of The Transplantation Society, Brighton, UK, 1982, (abstract No. F19.5). Google Scholar 96 P. A. Keown, C. R. Stiller, S. G. Carruthers, N. R. Sinclair, R. A. Ulan, and W. Howson, Monitoring of plasma levels and immunological effects of cyclosporin A in man, in Transplantation and Clinical Immunology, Vol. 13, Excerpta Medica, Amsterdam, 1981, p. 34. Google Scholar 97 P. A. Keown, C. R. Stiller, N. R. Sinclair, and R. A. Ulan, “Immunological and pharmacological monitoring in the clinical use of Cyclosporin A in renal transplantation,” Eur. Surg. Res., 13, 323 (1981). Web of Science®Google Scholar 98 P. A. Keown, C. R. Stiller, R. A. Ulan, N. R. Sinclair, W. J. Wall, and G. Carruthers, “Immunological and pharmacological monitoring in the clinical use of cyclosporin A,” Lancet, 1, 686 (1981). 10.1016/S0140-6736(81)91971-1 CASPubMedWeb of Science®Google Scholar 99 L. J. Kinlen, A. G. R. Sheil, J. Peto, and R. Doll, “Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs,” Br. Med. J., 2, 1461 (1979). 10.1136/bmj.2.6203.1461 CASPubMedWeb of Science®Google Scholar 100 A. J. Kostakis, D. J. G. White, and R. Y. Calne, “Toxic effects in the use of Cyclosporin A in alcoholic solution as an immunosuppressant of rat heart allografts,” IRCS Med. Sci. 5, 243 (1977). CASGoogle Scholar 101 A. J. Kostakis, D. J. G. White, and R. Y. Calne, “Prolongation of rat heart allograft survival by Cyclosporin A,” IRCS Med. Sci. 5, 280 (1977). CASGoogle Scholar 102 W. Land, L. A. Castro, G. Hillebrand, W. D. Illner, B. Schneider, W. Siebert, R. Zink, and E. Albert, “Immunosuppressive Basistherapie nach Nierentransplantation,” Fortschr. Med., 100, 1912 (1982). CASPubMedWeb of Science®Google Scholar 103 S. P. M. Lems and R. A. P. Koene, “Prolongation of mouse skin allograft survival by Cyclosporin A: graft rejection after withdrawal of therapy,” IRCS Med. Sci. 7, 184 (1979). CASGoogle Scholar 104 B. Leyland-Jones, A. Clark, W. Kreis, R. Dinsmore, R. O'Reilly, and C. W. Young, “High pressure liquid chromatographic determination of Cyclosporin-A in human plasma,” Res. Commun. Chem. Pathol. Pharmacol., 37, 431 (1982). CASPubMedWeb of Science®Google Scholar 105 R. Loertscher, F. Harder, F. P. Brunner, and G. Thiel, “Erste Erfahrungen mit Cyclosporin A bei Nierentransplantatempfängern in der Schweiz,” Schweiz. Med. Wschr., 112, 1865 (1982). Google Scholar 106 F. Lokiec, O. Poirier, E. Gluckman, and A. Devergie, Cyclosporin A: pharmaco-kinetic monitoring during treatment of graft-versus-host disease following bone marrow transplantation, in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 497. Google Scholar 107 J. J. Malatack, B. J. Zitelli, J. C. Gartner, Jr., B. W. Shaw, Jr., S. Iwatsuki, and T. E. Starzl, “Pediatric liver transplantation under therapy with cyclosporin A and steroids,” in 9th International Congress of The Transplantation Society, Brighton, UK, 1982 (Abstract No. F10.3). Google Scholar 108 F. N. McKenzie, C. R. Stiller, W. J. Wall, P. A. Keown, W. J. Silver, A. Painvin, and R. O. Heimbecker, “Cardiac transplantation with Cyclosporin A—clinical and experimental observations,” in 9th International Congress of The Transplantation Society, Brighton, UK, 1982 (abstract No. F11.4). Google Scholar 109 P. McMaster, J. Buckels, O. Gibby, J. Michael, M. Gillette, C. McCollum, M. Ezzibdeh, M. Gannon, M. Chamberlain, R. Y. Calne, K. Rolles, D. B. Evans, S. Thiru, and T. Duffy, Combined renal and pancreas transplantation with Cyclosporin A, in Cyclosporin A, D. J G. White, Ed., Elsevier, Amsterdam, 1982, p. 453. Google Scholar 110 P. McMaster, A. Procyshyn, R. Y. Calne, R. Valdes, K. Rolles, and D. J. Smith, “Prolongation of canine pancreas allograft survival with cyclosporin A: preliminary report,” Br. Med. J. 280, 444 (1980). 10.1136/bmj.280.6212.444 CASPubMedWeb of Science®Google Scholar 111 A. M. Miller, E. P. Walma, W. Klapwijk, and D. W. Van Bekkum, “The effect of cyclosporin-A on host-versus-graft disease in canine bone
Referência(s)